If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
▪ Presentation by Dr. Hervé Perron, Scientific Director of Geneuro at “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” of additional results of the NINDS / GeNeuro joint preclinical research program on amyotrophic lateral sclerosis (ALS)
▪ Results confirming the efficacy of the new anti-HERV-K monoclonal antibody from GeNeuro against the neurotoxicity mediated by HERV-K-ENV